Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 8/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239387 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CTSKCTSBCTSSOPRM1 | |
| SCHEMBL75648 | 0.77 | ALDH1A1 (0.44) | ALDH1A1NAAACTSKCTSBCTSS | |
| SCHEMBL14690433 | 0.72 | ALDH1A1 (0.40) | ALDH1A1CTSKCTSBCTSSCTSC | |
| SCHEMBL4634691 | 0.72 | CTSS (0.41) | ALDH1A1CTSKCTSBCTSSOPRM1 | |
| SCHEMBL13600125 | 0.70 | OPRM1 (0.43) | ALDH1A1NAAACTSKCTSSOPRM1 | |
| SCHEMBL5671761 | 0.67 | OPRM1 (0.53) | ALDH1A1OPRM1TSHR | |
| SCHEMBL16486133 | 0.67 | ALDH1A1 (0.38) | ALDH1A1CTSKCTSSOPRM1TSHR | |
| SCHEMBL3241413 | 0.67 | OPRM1 (0.50) | ALDH1A1CTSKCTSSOPRM1TSHR | |
| SCHEMBL18922802 | 0.66 | ALDH1A1 (0.37) | ALDH1A1CTSKCTSSOPRM1TSHR | |
| SCHEMBL4446952 | 0.66 | CTSS (0.41) | ALDH1A1NAAACTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | claimed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | claimed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | claimed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | claimed |
| US-6835727-B2 | Bone disorders; osteoporosis; rheumatic diseases | MERCK FROSST CANADA & CO. (CA) | 2004-12-28 | — | — | US | disclosed |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | disclosed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | disclosed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | CTSK, CTSZ, CTSE | ALDH1A1 4445/4885NAAA 1206/4885CTSK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.